EMERYVILLE, Calif. and MELBOURNE, Australia, Nov. 9, 2022
/PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in
digital cell biology, today announced Monash University, one of
Australia's leading universities,
has implemented the use of the Berkeley Lights Beacon® system and
Opto® Plasma B Discovery workflow for antibody discovery research.
The technology is housed in the Monash Antibody Technology Facility
(MATF) where researchers not only from Monash University but
elsewhere in Victoria, Australia
and worldwide can utilize their services for antibody production,
assay development, robotics, high throughput screening and antibody
characterization.
Since acquiring the Beacon Platform in early 2022, MATF
scientists have developed significant expertise in using the
Berkeley Lights technology and workflows. Specifically, the Beacon
Platform has enabled them to expand their antibody discovery
capacity beyond traditional hybridoma techniques, allowing them to
offer a wider portfolio to their customers especially those with
difficult targets using the Beacon single B cell-screening
platforms for rapid antibody discovery.
In addition to MATF, Dr. Remy
Robert, head of the Robert
Lab associated with the Monash Biomedicine Discovery
Institute, and a member of the Immunity Program and the Department
of Physiology, and Biochemistry & Molecular Biology, is
utilizing the Beacon Platform. Dr. Robert and other lab associates
are developing new classes of therapeutic mAbs against difficult
targets using cutting-edge technologies like the Beacon Platform in
mAbs development, engineering, and pre-clinical validation.
Dr. Yue Geng, general manager of the Platform business at
Berkeley Lights, said, "We are pleased to be partnering with the
Monash Antibody Technology Facility at Monash University and
supporting their scientists in their adoption of the Berkeley
Lights Platform for antibody discovery. Monash University has
quickly adopted our advanced technology to further their scientific
expertise and enable the advancement of critical therapeutics to
market. We look forward to enabling Monash University as one of the
world's leading high-impact research institutions."
Some of the research advantages that Monash has experienced to
date by using the Beacon Platform include:
- Accelerating the screening of primary B cells on the Berkeley
Lights Beacon system for antibody discovery by weeks compared to
the standard hybridoma process;
- Facilitating rapid screening of thousands of single plasma
cells on the same day as cell isolation; and
- Identifying target-binding candidates in just one day, and
sequencing of variable chains as well as generating recombinant
antibodies in 2–4 weeks.
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company
focused on enabling and accelerating the rapid development and
commercialization of biotherapeutics and other cell-based products
for our customers. The Berkeley Lights Platform captures deep
phenotypic, functional, and genotypic information for thousands of
single cells in parallel and can also deliver the live biology
customers desire in the form of the best cells. Our platform is a
fully integrated, end-to-end solution, comprising proprietary
consumables, including our OptoSelect® chips and reagent kits,
advanced automation systems, and application software. We developed
the Berkeley Lights Platform to provide the most advanced
environment for rapid functional characterization of single cells
at scale, the goal of which is to establish an industry standard
for our customers throughout their cell-based product value
chain.
About Monash University
Monash University is Australia's largest university with more than
80,000 students. In the 60 years since its foundation, it has
developed a reputation for world-leading high-impact research,
quality teaching, and inspiring innovation. With four campuses in
Australia and a presence in
Malaysia, China, India,
Indonesia, and Italy, it is one of the most internationalized
Australian universities. As a leading international medical
research university with the largest medical faculty in
Australia and integration with
leading Australian teaching hospitals, Monash University
consistently ranks in the top 50 universities worldwide for
clinical, pre-clinical and health sciences.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Berkeley Lights
or its products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
Berkeley Lights undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/monash-university-implements-antibody-discovery-application-by-utilizing-the-berkeley-lights-beacon-platform-301673695.html
SOURCE Berkeley Lights, Inc.